Mirum Pharmaceuticals (STU:08D) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


STU:08D Mirum Pharmaceuticals Inc STU:08D
47 GF Score
Price €100.85
GF Value €66.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Mirum Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:08D vs APGE, PTCT, RYTM: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Mirum Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirum Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


STU:08D
47GF Score
Mirum Pharmaceuticals Inc STU:08D
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €100.85 is trading 51.3% above its estimated GF Value™ of €66.66. GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:08D:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €66.66 vs. price of €100.85 (51.3% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
47GF Score

Get the complete analysis for STU:08D

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€100.85
Price
€66.66
GF Value